Pregabalin Significantly Improves Neuropathic Pain

This article originally appeared here.
Share this content:
Pregabalin Significantly Improves Neuropathic Pain
Pregabalin Significantly Improves Neuropathic Pain

FRIDAY, Sept. 9, 2016 (HealthDay News) -- Pregabalin significantly improves neuropathic pain, irrespective of the time since pain onset, according to a study published online Sept. 2 in Pain Practice.

Concepción Pérez, Ph.D., from the Hospital de la Princesa in Madrid, and colleagues conducted a pooled analysis of 19 randomized placebo-controlled trials of pregabalin for peripheral neuropathic pain conditions (including diabetic peripheral neuropathy, postherpetic neuralgia, and posttraumatic/postsurgical pain). Patients were divided into five categories according to time since onset of pain. For each category, the mean change in pain score at end point was assessed versus placebo. Data were included for 5,783 patients (3,619 pregabalin-treated and 2,164 placebo-treated).

The researchers found that across pain duration categories, the mean baseline pain scores were similar. In all patients together, pregabalin significantly improved pain score at end point versus placebo (treatment difference, −0.59); similar results were seen in each pain duration category. Significantly more Patient Global Impression of Change responders were seen with pregabalin versus placebo for all patients (45 versus 30.9 percent) and for each category separately. No consistent, significant differences in treatment response were seen between the different categories of pain duration.

"Pregabalin significantly improves pain irrespective of the length of time since onset of neuropathic pain," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which manufactures pregabalin and funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »